VIDEO: Faricimab a step into new era of longer-lasting retinal disease therapies

At the virtual Euretina congress, Francesco Bandello, MD, speaks about faricimab, a drug that combines anti-VEGF and Ang-2-blocking properties.
The phase 2 BOULEVARD trial for diabetic macular edema and AVENUE and STAIRWAY trials for age-related macular degeneration have shown positive, long-lasting therapeutic effects.

Full Story →